Axiom MRC has updated all it's market research reports with the Economic Impact Analysis of COVID19 Pandemic on the market. Our team of analyst are following Comprehensive Three Dimensional (3D) Research Methodology along with large number primary interviews with key industry participants to bring insightful market reports to meet the current market requirements.
The role of artificial wound care biologics in burn surgery and the therapy of chronic wounds is continually evolving. The absence or loss of skin, because of the resulting drain of fluids and protein and due to the risk of invasive infection, requires wound closure with a skin substitute. New products are regularly being produced and approved for clinical use. Presently, with headway in research and studies, wound care biologics such as biotechnologically engineered skin and topical agents have transformed the wound healing process making it easier and convenient. Also, key industry players create differentiation in the product offerings that creates numerous growth opportunities.
There are numerous factors that will propel growth in the global wound care biologics market. The increasing diabetic population is the major factor attributing to the growth market. Diabetes has become a common affair among all developed and developing nations. The rate of incidence of diabetes is increasing every year, thus paving way for players in the treatment market. One of the gainers is the wound care biologics market. As indicated by the International Diabetes Federation, approximately 425 million adults were living with diabetes in 2017 and this number is expected to reach 629 million in 2045. And the numbers are likely to increase in coming years. The growing number of diabetes paving way for players in the treatment market including wound care biologics market.
Also, increase in burn injuries, expanding geriatric population are also opening new avenues for players in the global wound care biologics market. On the downside, the high cost of wound care biologics coupled with the high rejection rate linked with skin grafts is likely to limit the growth of the market.
The report analyses the global wound care biologics market based on product, wound type, end user and geography.
Wound care market by product is categorised into, biological skin substitutes, biosynthetic products and topical agents biological skin substitute includes human donor tissue-derived products and acellular animal-derived products. Biologic substitutes act temporarily like skin, have the advantages of being relatively abundant in supply and not expensive. The biological skin substitutes offer the construction of a more natural new dermis and allow excellent re-epithelialisation characteristics due to the presence of a basement membrane. Whereas Synthetic skin substitutes demonstrate the advantages of increase control over scaffold composition.
The wound care biologics aids in the healing of wounds such as ulcers, surgical and traumatic wounds and burns. The ulcers segment includes venous ulcers, diabetic foot ulcers, pressure ulcers. The increasing prevalence of diabetes acts as a key factor for the growth of ulcer segment. According to the American Diabetes Association data, nearly 29 million of the Americans will be diagnosed with diabetes by 2050. Diabetic foot ulcers have negative impact on patient, due to its high probability of contamination and resulting into an amputation. Hence management of diabetes ulcers becomes utmost important in such cases thereby stimulating demand for effective treatment including wound biologicals.
The major end users of the market are hospitals, ASCs, burn centres and wound clinics. Among all end users of wound care biologics, high demand for amniotic membrane is expected to come from the hospitals segment owing to increasing application of wound care biologics in advanced surgical healing.
Based on geography, the global wound care biologics market is segmented into North America, Europe, Asia Pacific and Rest of the World. North America dominated global amniotic membrane market in 2019, owing to the increase in number of patients suffering from diabetes and vascular ulcers, high demand for minimally invasive procedures, and the growth in geriatric population majorly drive the market growth. The Asia-Pacific attracting the patient population from developed countries for the effective treatment at low cost.
Key players in the global Wound Care Biologics market include Smith & Nephew , Mölnlycke Health Care AB (Investor AB) , Integra Lifesciences , Wright Medical , Mimedx Group , Vericel , Anika Therapeutics , Osiris Therapeutics , Organogenesis , Kerecis , Solsys Medical , Acell , and Marine Polymer Technologies among others.
January 2019: Generex Biotechnology Corporationcompleted the acquisition of 51% of Olaregen Therapeutix Inc., a New York based regenerative medicine company that is preparing to launch its proprietary, patented, wound conforming gel matrix, Excellagen an FDA 510K Cleared wound healing product cleared for the treatment of 17 types of wounds.
August 2017: Skye Biologics secured multiyear agreements to provide WoundEx Fastacting amniotic membrane for outpatient wound care with New York City Health and Hospitals Corporation (HHC), and Prohealth Medical Management and Prohealth Care Associates two of the largest healthcare networks in New York.
The report analyses the global wound care biologics market based on product, wound type, end user ad geography. Wound care market by product is categorised into, biological skin substitutes, biosynthetic products and topical agents biological skin substitute includes human donor tissue-derived products and acellular animal-derived products. The wound care biologics aids in the healing of wounds such as ulcers, surgical and traumatic wounds and burns. The ulcers segment includes venous ulcers, diabetic foot ulcers, pressure ulcers. The major end users of the market are hospitals, ASCs, burn centres and wound clinics. Based on geography, the global wound care biologics market is segmented into North America, Europe, Asia Pacific and Rest of the World.
Key players in the global Wound Care Biologics market include Smith & Nephew , Mölnlycke Health Care AB (Investor AB) , Integra Lifesciences , Wright Medical , Mimedx Group , Vericel , Anika Therapeutics , Osiris Therapeutics , Organogenesis , Kerecis , Solsys Medical , Acell , and Marine Polymer Technologies among others.
Why to buy this report:
